InspireMD raises $23M for MGuard stent | Wall Street Beat

MassDevice.com Wall Street Beat

InspireMD (OTC:NSPR) said it added some $23 million to its coffers in a public stock offering.

The Tel Aviv-based medical device company makes the MGuard device, designed to protect against embolism after stenting procedures.

InspireMD said it plans to put the $22.6 million in net proceeds from the sale of 12.5 million shares at $2 per to a variety of uses.

Sign up to get our free newsletters delivered straight to your inbox

Apart from retiring some debt, the company plans to use the cash to fund further commercialization for its MGuard carotid stent system, which won CE Mark approval in the European Union last month, according to a regulatory filing.

InspireMD said it also plans to use the money to pursue U.S. approval of the coronary and carotid devices and "for general corporate purposes," according to the filing.

"Following this offering, the company will not have any indebtedness for borrowed money outstanding," InspireMD said.

NSPR shares were trading at $1.95 apiece as of about noon today, up 1.0%.

 Zoll, Reflectance Medical ink pact to develop combat monitor
Zoll Medical (NSDQ:ZOLL) and Reflectance Medical inked a pact to develop and market a "ruggedized" version of Reflectance’s Mobile CareGuide sensor for detecting shock during air and ground transport for military and civilian patients. The device is designed to monitor tissue metabolism to determine undetected internal bleeding leading to shock.
Read more

 MiMedx issues $6M in shares in Surgical Biologics earnout
MiMedx (OTC:MDXG) said it issued nearly 1.21 million shares of stock worth about $5.8 million for "earn-out consideration related to the acquisition of Surgical Biologics" based on "a formula determined by sales and certain expenses" during 2012. MiMedx acquired Surgical Biologics and its AmnioFix technology in 2011.
Read more

 Terumo signs distribution deals with BSD Medical, Nonin Medical
Terumo Corp. (TYO:4543) signed distribution deals with BSD Medical Corp. (NSDQ:BSDM) and Nonin Medical. The deal with BSD covers sales of that company’s MicroThermX microwave ablation system in 100 countries in Europe, Western Asia, and Northern Africa. The deal with Nonin covers distribution of that firm’s Equanox 7600 oximetry system in the U.S.
Read more

 U.S. Defense Dept. doles out medtech contracts
The U.S. Defense Dept. issued contracts for a variety of medical technologies to 4 companies, including an $86 million deal with Combat Medical Systems for tactical medical equipment; a $41.5 million contract modification for Dental Health Products for general dental supplies; another modification worth $23.2 million for Henry Schein (NSDQ:HSIC) for lab supplies; and another lab supplies contract modification for Cardinal Health (NYSE:CAH) worth $18.6 million.

 Analysts’ ups and downs

  • Abbott (NYSE:ABT): Barclays reiterates “equal weight” rating; Credit Suisse initiates coverage with "neutral" rating, $40 price target; Deutsche Bank raises price target from $33 to $35; Leerink Swann reiterates "market perform" rating, raises price target to $40 from $32-$34.
  • Amgen (NSDQ:AMGN): Citi boosts earnings estimates through 2014, sets $133 price target.
  • Baxter (NYSE:BAX): Leerink Swann reiterates “outperform” rating, increases price target to $78 from $74;
  • Piper Jaffray maintains "overweight" rating, raises price target to $81.
  • Becton Dickinson & Co. (NYSE:BDX): Deutsche Bank maintains “hold” rating, raises price target to $94.
  • Boston Scientific (NYSE:BSX): Deutsche Bank raises price target from $7.20 to $7.90; “hold” rating;
  • JMP Securities reissues "market outperform" rating; $9 price target; Morgan Stanley initiates coverage with "overweight" rating.
  • Edwards Lifesciences (NYSE:EW): Leerink Swann maintains “outperform” rating, $100 price target
  • Haemonetics (NYSE:HAE): Zacks Equity Research downgrades back to “neutral” rating
  • Intuitive Surgical (NSDQ:ISRG): Leerink Swann lowers price target to ~$560 from $580, maintains “market perform” rating; SunTrust reaffirms "buy" rating, $649 price target.
  • Johnson & Johnson (NYSE:JNJ): Leerink Swann reiterates “outperform” rating, raises price target to $88 from $80.
  • Life Technologies (NSDQ:LIFE): Piper Jaffray reiterates “neutral” rating, raises price target from $63 to $76.
  • Mako Surgical (NSDQ:MAKO): Leerink Swann maintains “market perform” rating, raises price target to $14 from $12-$13.
  • Medtronic (NYSE:MDT): Deutsche Bank raises price target from $46 to $51; “hold” rating; TheStreet reissues "buy" rating.
  • Optos plc (LON:OPTS): N+1 Singer reiterates “sell” rating; £1.50 ($2.30) price target
  • Smith & Nephew (FTSE:SN, NYSE:SNN): Deutsche Bank reaffirms “hold” rating, $638 price target; JPMorgan Chase reiterates "neutral" rating, sets £7.09 ($10.88) price target.
  • St. Jude Medical (NYSE:STJ): Barclays reiterates “overweight” rating; Deutsche Bank maintains "buy" rating, raises price target to $52; Deutsche Bank maintains "buy" rating, raises price target to $52; Leerink Swann maintains "outperform" rating, ~$50 price target.
  • Thermo Fisher (NYSE:TMO): Jefferies raises price target from $80 to $95, maintains “buy” rating.
  • Varian Medical (NYSE:VAR): Morgan Stanley downgrades to “underweight” rating, $65 price target.

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply